Published in Blood Weekly, March 9th, 2006
The company has $5 million remaining in a $25 million stock repurchase program previously authorized by the company, which it intends to exhaust before utilizing the repurchase program newly authorized.
The number of shares to be purchased and the timing of such activity will be dependent on several conditions, including the price of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.